| Bioactivity | Madrasin (DDD00107587) is a splicing inhibitor that prevents formation of both splicing intermediates and products in vitro and interferes with one or more early steps in the pathway of spliceosome assembly. Madrasin also can inhibit pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA in cells[1]. | ||||||||||||
| Target | pre-mRNA splicing | ||||||||||||
| Invitro | Madrasin (10-30 μM; 4-24 hours; HeLa cells) treatment inhibits the splicing of each of the RIOK3, BRD2, and Hsp40, MCL1, CCNA2, AURKA and p27 pre-mRNAs in both HeLa and HEK293 cells[1].Madrasin (10-30 μM; 4-24 hours; HeLa and HEK293 cells) treatment shows a dose- and time-dependent inhibitory effect on cell cycle progression[1]. RT-PCR[1] Cell Line: | ||||||||||||
| Name | Madrasin | ||||||||||||
| CAS | 374913-63-0 | ||||||||||||
| Formula | C16H17N5O2 | ||||||||||||
| Molar Mass | 311.34 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Andrea Pawellek et al. Identification of Small Molecule Inhibitors of Pre-mRNA Splicing. J Biol Chem, 2014 Dec 12, 289(50): 34683-34698. |